Respiratory

ReAlta begins subject enrolment in Phase II trial of AE-COPD treatment

ReAlta Life Sciences has enrolled the first subject in a Phase II clinical trial of its investigational drug RLS-0071, aimed…

Vertex hopes to fast-track approval of CF therapy on heels of positive Phase III data

Vertex Pharmaceuticals will be using its priority review voucher with the US Food and Drug Administration (FDA) with hopes of…

ECDC report suggests respiratory infections could surge this winter

Bacterial and viral respiratory infections contribute to morbidity and mortality every winter. Those over the age of 65 years have…

Clarametyx launches Phase Ib/IIa cystic fibrosis therapy trial

US-based Clarametyx Biosciences is starting the enrolment for its Phase Ib/IIa trial investigating CMTX-101 as an adjunctive therapy for patients…

Ethris doses first patient with antiviral mRNA drug in Phase I asthma trial

Ethris has dosed the first participant with its inhaled mRNA therapy ETH47 as part of a Phase I trial evaluating…

MHRA approves Ethris’ Phase I trial for inhaled mRNA drug

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ethris’s Phase I trial to investigate its inhaled mRNA…

Sanofi and Regeneron’s Dupixent scores second win in Phase III COPD trial

Sanofi and Regeneron have reported positive interim data from the Phase III NOTUS trial with Dupixent (dupilumab) showing a 34%…

Viatris and Theravance report data from COPD treatment trial

Viatris and Theravance Biopharma have reported positive data from the Phase III clinical trial of Yupelri (revefenacin) as a maintenance…

MAIA’s lung cancer therapy offers complete disease control in trial

MAIA Biotechnology has reported that treatment with THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) in sequential combination with cemiplimab (Libtayo) offered 100% disease control…

BiomX completes subject dosing in trial to treat pulmonary infections

BiomX has completed the dosing of patients with cystic fibrosis (CF) in Part II of its Phase Ib/IIa clinical trial…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close